2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - New Orleans Theatre C
Treatment Considerations, Combination Therapy, Therapy Sequence, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Hodgkin Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Study Population, Human, Adult
PAPER

1026 A Phase II study of PET-adapted therapy with nivolumab-AVD (doxorubicin, vinblastine, dacarbazine) for advanced-stage Hodgkin lymphoma

Kishan Patel, MD, Esther Drill, DrPH2, Kerry Savage, MD, MSc, BSc3, Tatyana Feldman, MD4, Nivetha Ganesan, MPH5, Helen Hancock, NP6, Theresa Davey, PA7, Leslie Perez, RN8, Alayna Santarosa9, Sarima Subzwari, MS10, Catherine Yang11, Natasha Galasso, MSW12, Kevin David, MD13, Zachary Epstein-Peterson, MD14, Anita Kumar, MD15, Paul Hamlin, MD16, Paola Ghione, MD, MS17, Jennifer Kimberly Lue, M.D.18, Colette Owens, MD19, Andrew Intlekofer, MD, DPhil20, Steven Horwitz, M.D.21, Lorenzo Falchi, MD22, Maria Lia Palomba, MD23, Ariela Noy, MD24, Gilles Salles I, MD, PhD25, Pallawi Torka, MD26, Santosha Vardhana, MD, PhD27, Joachim Yahalom, MD28, Ahmet Dogan, MD29, Andrew Zelenetz, MD30, Heiko Schoder, MD31, Alison Moskowitz, MD32
1 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
3 BC Cancer, Vancouver, Canada
4 Hackensack Meridian Health, Hackensack, New Jersey, United States
5 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
28 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
29 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
30 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
31 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
32 Memorial Sloan Kettering Cancer Center, New York City, New York, United States

Background: The RATHL study demonstrated that ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) followed by PET-adapted therapy is a reasonable treatment strategy for patients with advanced-stage classic Hodgkin lymphoma (cHL). In RATHL, patients who attained PET-2 negativity after ABVD(x2) were treated with AVD and had 7-year PFS of 79%, while those who were PET-2 positive were treated with BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), with 7-year PFS of 66%. Given the efficacy of anti-PD1 immunotherapy (ICB) in cHL, we hypothesized that incorporation of ICB into PET-adapted therapy after ABVD(x2) would lead to similar outcomes for patients with PET-2 positive disease.

Methods: This was an investigator-initiated, single-arm, phase II trial conducted at Memorial Sloan Kettering, Hackensack Health, BC Cancer, and Karmanos Cancer Institute (ClinicalTrials.gov, NCT03033914, Cohort A). Eligible patients had biopsy-proven stage III or IV cHL and were aged 18-60 years. Patients received ABVD (doxorubicin 25mg/m2, bleomycin 10 units/m2, vinblastine 6mg/m2, and dacarbazine 375mg/m2 on day 1 and day 15 of each 28-day cycle)(x2); those with negative results on PET-2 (Deauville 1, 2, or 3) received 4 additional cycles of AVD (with omission of bleomycin), while those with positive results on PET-2 (Deauville 4 or 5) received 4 cycles of nivolumab-AVD (nivolumab 240mg included on day 1 and day 15). Prophylactic G-CSF support was not mandated. Patients at MSK were allowed to enroll during the first two cycles of ABVD; patients at other institutions were enrolled after PET-2 demonstrated positive results. The primary endpoint was PFS for PET-2 positive patients; secondary endpoints included PFS for PET-2 negative patients and overall survival (OS). Exploratory endpoints included assessment of serum TARC (thymus and activation-regulated chemokine).

Results: 39 patients were enrolled. The median age was 35 years (IQR 26-43) and 59% of patients were men. At diagnosis, 26% of patients had Lugano stage III disease and 74% of patients had stage IV disease. Twelve patients (31%) were IPS “low-risk” (0-1), 15 patients (38%) “intermediate-risk” (2-3), and 12 patients (31%) “high-risk” (4+). Of the 39 patients, 20 patients were PET-2 negative after ABVD(x2) and were treated with AVD(x4), while 19 patients were PET-2 positive and were treated with nivolumab-AVD(x4). Of the 19 patients who were PET-2 positive, 13 (68%) were enrolled from non-MSK institutions.

After a median follow-up of 5.7 years (IQR 4.5-6.6), among patients who were PET-2 positive, there were 7 events: 2 patients were primary refractory and 5 patients relapsed, all within 2 years of end-of-treatment (EOT). Of the 5 PET-2 positive patients who relapsed, 1 relapsed with features of mediastinal gray zone lymphoma, and 1 relapsed with T-cell histiocyte-rich B-cell lymphoma. Estimated 5-year PFS for PET-2 positive patients was 60% (95% CI 41-88%) and OS was 100%. Among patients who were PET-2 negative, there were 3 events: 1 patient was primary refractory and 2 patients relapsed, both within 2 years of EOT. Estimated 5-year PFS for PET-2 negative patients was 85% (95% CI 71-100%) and OS was 93% (95% CI 82-100%). Grade 3+ AEs that were identified for PET-2 positive patients included neutropenia (32%), febrile neutropenia (11%), pneumonia (5%), pneumonitis (5%), and premature menopause (5%).

Among the 19 PET-2 positive patients, serum TARC was available at C3D1 for 9 patients (47%) and was elevated (>1,000pg/mL) in only 1 patient despite radiographic findings. EOT TARC was available for 9 PET-2 positive patients (47%) and was elevated in 1 patient with primary refractory disease. Of the 8 patients with “normal” EOT TARC, 1 had primary refractory disease, 2 relapsed 7 months and 10 months after EOT, and 5 remained progression-free at last follow-up.

Conclusion: For patients with advanced-stage cHL who are PET-2 positive after ABVD(x2), escalation to nivolumab-AVD led to favorable outcomes, with similar long-term PFS to that reported in RATHL with escalation to BEACOPP. This study is limited by small sample size. In the era of SWOG1826, response-adapted use of ICB may still be relevant for resource-limited settings, where access to ICB for all patients may be restricted. Lastly, in this cohort, serum TARC levels had limited utility in identifying patients at high risk of relapse after front-line therapy.

Kishan Patel, MD: No relevant conflicts of interest to declare.